News & Updates

Second-line treatment with adagrasib plus cetuximab demonstrates manageable safety but results in no statistically significant improvement in both progression-free (PFS) and overall survival (OS) in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) compared with chemotherapy, results of the KRYSTAL-10 trial have shown.

A retrospective cohort study conducted in Hong Kong among adults with co-existing asthma and diabetes mellitus (DM) has found a lower risk of asthma exacerbation with glucagon-like peptide-1 receptor agonist (GLP-1 RA) vs dipeptidyl peptidase-4 inhibitor (DPP-4i) treatment.

People living with HIV (PWH) may soon benefit from a once-weekly treatment regimen instead of the standard daily antiretroviral therapy to manage their condition. Two recent phase III trials, ISLEND-1 and -2, have shown the efficacy of islatravir/lenacapavir (ISL/LEN) vs bictegravir/emtricitabine/tenofovir/alafenamide (B/F/TAF) or standard of care (SOC).